Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility

Journal of Medical Genetics

Volumn 39, Issue 4, 2002, Pages 225-242

  De Jong, M M ^a   Nolte, I M ^a   Te Meerman, G J ^a   Van der Graaf, W T A ^a   Oosterwijk, J C ^a   Kleibeuker, J H ^a   Schaapveld, M ^b   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Integraal Kankercentrum Noord Nederland   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0036247145     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.39.4.225     Document Type: Review

References (338)

1. Epidemiology of cancer: Global patterns and trends
2. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction
3. The genetic epidemiology of cancer
4. The genetics of breast and ovarian cancer
5. Genetic heterogeneity in hereditary breast cancer: Role of BRCA1 and BRCA2
6. Genetics of breast cancer
7. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
8. Breast cancer genes - What are the real risks?
9. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families
10. Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer-susceptibility genes?
11. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians
12. Genetic and hormonal risk factors in breast cancer
13. Inherited genetic predisposition in breast cancer. A population-based perspective
14. Genetic heterogeneity in breast cancer susceptibility
15. Relevance of high and low penetrance
16. Genetics of CYP1A1: Coamplification of specific alleles by polymerase chain reaction and association with breast cancer
17. Metabolic polymorphisms and cancer susceptibility
18. A polymorphism in the CYP17 gene increases the risk of breast cancer
19. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer
20. Genetic polymorphisms and risk of breast cancer
21. A systematic review of genetic polymorphisms and breast cancer risk
22. Mechanisms of carcinogenesis and individual susceptibility to cancer
23. Mutation and childhood cancer: A probabilistic model for the incidence of retinoblastoma
24. Alterations in DNA methylation: A fundamental aspect of neoplasia
25. Cancer epigenetics comes of age
26. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer
27. Loss of heterozygosity and linkage analysis in breast carcinoma: Indication for a putative third susceptibility gene on the short arm of chromosome 8
28. Strong indication for a breast cancer susceptibility gene on chromosome 8p 12-p22: Linkage analysis in German breast cancer families
29. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers
30. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer
31. Genome-wide search far loss of heterozygosity shows extensive genetic diversity of human breast carcinomas
32. Deletion mapping and linkage analysis provide strong indication far the involvement of the human chromosome region 8p12-p22 in breast carcinogenesis
33. Chromosome region 8p11-p21: Refined mapping and molecular alterations in breast cancer
34. Identification of a 5-cM region of common allelic loss on 8p12-p21 in human breast cancer and genomic analysis of the hEXT1L/EXTR1/EXTL3 gene in this locus
35. Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cM interval of 8p22-p23.1
36. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer
37. Loss of heterozygosity on the short arm of chromosome 8 in male breast carcinomas
38. Allelic loss of chromosomal arm 8p in breast cancer progression
39. Sequence-ready contig for the 1.4-cM ductal carcinoma in situ loss of heterozygosity region on chromosome 8p22-p23
40. Positional cloning of the Werner's syndrome gene
41. Recurrent HSR in the centromeric region of chromosome 8 in breast cancer
42. A 2.8 megabase YAC contig spanning D8S339, which is tightly linked to the Werner syndrome locus
43. The p53 tumour suppressor gene
44. Germline p53 mutations and heritable cancer
45. Clinical implications of the p53 tumor-suppressor gene
46. Follow-up study of twenty-four families with Li-Fraumeni syndrome
47. Mutations in p53 do not account for heritable breast cancer: A study in five affected families
48. Screening for germ line TP53 mutations in breast cancer patients
49. Constitutional p53 mutation in a non-Li-Fraumeni cancer family
50. Inherited p53 gene mutations in breast cancer
51. Screening for germline mutations of the p53 gene in familial breast cancer patients
52. Mutations in the p53 gene in primary human breast cancers
53. p53 mutations in breast cancer
54. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters
55. Loss of heterozygosity and p53 gene mutations in breast cancer
56. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
57. Racial disparity in the association of p53 gene alterations with breast cancer survival
58. Mutation and methylation status of p53 gene promoter in human breast tumours
59. p53 polymorphisms and haplotypes in different ethnic groups
60. p53 polymorphism in ovarian and breast cancer
61. p53 polymorphisms and haplotypes in breast cancer
62. p53 haplotype determination in breast cancer
63. p53 germline polymorphisms are associated with an increased risk far breast cancer in German women
64. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients
65. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer
66. A novel polymorphism in intron 6 of the human p53 gene: A possible association with cancer predisposition and susceptibility
67. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer
68. Breast and other cancers in families with ataxia-telangiectasia
69. Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations
70. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain
71. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia
72. Cancers in 44 families with ataxia-telangiectasia
73. Incidence of cancer in 161 families affected by ataxia-telangiectasia
74. Cancer risks in A-T heterozygotes
75. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer
76. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: Haplotype study in French AT families
77. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer
78. The inherited component of cancer
79. ATM mutations in cancer families
80. The role of ataxia-telangiectasia heterozygotes in familial breast cancer
81. The ATM gene and susceptibility to breast cancer: Analysis of 38 breast tumors reveals no evidence for mutation
82. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer
83. Heterozygous ATM mutations do not contribute to early onset of breast cancer
84. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer
85. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor
86. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility
87. Cancer risk in ATM heterozygotes: A model of phenotypic and mechanistic differences between missense and truncating mutations
88. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene
89. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
90. Germline carriers of ATM mutations are prevalent among Austrian hereditary breast and ovarian cancer (HBOC) patients
91. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
92. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation
93. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome
94. The Cowden syndrome: A clinical and genetic study in 21 patients
95. Genetics of Cowden syndrome: Through the looking glass of oncology
96. The role of MMAC1 mutations in early-onset breast cancer: Causative in association with Cowden syndrome and excluded in BRCA1-negative cases
97. A study of the PTEN/MMAC1 gene in 136 breast cancer families
98. Polymorphisms in PTEN in breast cancer families
99. No evidence for germline PTEN mutations in families with breast and brain tumours
100. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas
101. Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers
102. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas
103. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma
104. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
105. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer
106. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus
107. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
108. Increased risk of cancer in the Peutz-Jeghers syndrome
109. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome
110. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase
111. Increased risk for cancer in patients with the Peutz-Jeghers syndrome
112. Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p
113. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer
114. Low penetrance genes associated with increased risk for breast cancer
115. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells
116. Complete nudeotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue
117. Detection of cancer predisposition by hypervariable region analysis
118. Minisatellite allele diversification: The origin of rare alleles at the HRAS1 locus
119. High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients
120. RFLPs of the Ha-ras 1 proto-oncogene in subjects with colon-rectal carcinomas
121. Comparison between the allelic frequency distribution of the Ha-ras 1 locus in normal individuals and patients with lymphoma, breast, and ovarian cancer
122. Increased frequency of specific alleles of the c-Ha-fas gene in Japanese cancer patients
123. Partial deletion of chromosome 11p in breast cancer correlates with size of primary tumour and oestrogen receptor level
124. Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population
125. c-Ha-ras-1 polymorphism in human breast carcinomas: Evidence for a normal distribution of alleles
126. Polymorphism of the c-Ha-ras-1 proto-oncogene in sporadic and familial breast cancer
127. Rare HRAS alleles and susceptibility to human breast cancer
128. HRAS proto-oncogene polymorphism and breast cancer
129. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus
130. HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years
131. Specific H-Ras minisatellite alleles in breast cancer susceptibility
132. The analysis of restriction fragment length polymorphism in human cancer: A review from an epidemiological perspective
133. Correlation of L-myc genotypes to metastasis of gastric cancer and breast cancer
134. Association between restriction fragment length polymorphism of the l-myc gene and lung metastasis in human breast cancer
135. L-myc polymorphism in cancer patients, healthy blood donors and elderly, tumor-free individuals in Russia
136. Metabolism of debrisoquine and susceptibility to breast cancer
137. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes
138. Defining etiologic heterogeneity in breast cancer using genetic biomarkers
139. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder
140. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT1 * 10 allele with higher N-acetylation activity in bladder and colon tissue
141. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe
142. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer
143. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk
144. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk
145. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
146. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
147. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: Application to metabolic epidemiology
148. Acetylator phenotype in patients with breast cancer
149. Hepatic acetylator polymorphism in breast cancer patients
150. Acetylator status and its relationship to breast cancer and other diseases af the breast
151. Drug acetylation in breast cancer
152. Acetylation phenotype is not associated with breast cancer
153. Polymorphic N-acetylation capacity in breast cancer patients
154. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients
155. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk
156. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer
157. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence
158. N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women
159. Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype
160. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
161. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: A follow up study
162. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types
163. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility
164. Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: Relevance to environmental carcinogenesis?
165. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer
166. Expression of GST-mu transferase in breast cancer patients and healthy controls
167. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk
168. Glutathione S-transferase class mu deletion polymorphism and breast cancer: Results from prevalent versus incident cases
169. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: Evidence of a lack of association in Caucasians and African Americans
170. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer
171. Allelic deletion at glutathione S-transferase M1 locus and its association with breast cancer susceptibility
172. Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: Relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients
173. Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants
174. Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility
175. Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility
176. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility
177. Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk
178. The association between gluathione S-transferase M1 genotype and polycyclic aromatic hydrocarbon-DNA adducts in breast tissue
179. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
180. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties
181. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer
182. Gene deletion of glutathione S-transferase theta: Correlation with induced genetic damage and potential role in endogenous mutagenesis
183. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism
184. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta
185. Role of genetics and drug metabolism in human cancer risk
186. Genetic linkage of lung cancer-associated Mspl polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene
187. The CYP1A1 gene and cancer susceptibility
188. Study of the frequencies of CYP1A1 gene polymorphisms and glutathione S-transferase mu1 gene in primary breast cancers: An update with an additional 114 cases
189. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study
190. Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan
191. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk
192. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk
193. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity
194. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer
195. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer
196. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer
197. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility
198. Debrisoquine hydroxylase gene polymorphism in neurofibromatosis type 1
199. Cytochrome P450dbl phenotypes in malignant and benign breast disease
200. Polymorphic oxidation of debrisoquine in women with breast cancer
201. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility
202. CYP2D6 genotypes in Spanish women with breast cancer
203. The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients
204. Does estrogen receptor expression in normal breast tissue predict breast cancer risk?
205. Endogenous sex hormone levels and breast cancer risk
206. Epidemiologic analysis of breast and gynecologic cancers
207. Reproductive factors and breast cancer
208. Hormonal carcinogenesis
209. Free radical generation by redox cycling of estrogens
210. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?
211. Estrogens and breast cancer
212. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17
213. Cytochrome P450c17 alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations
214. A polymorphism in the CYP17 gene is associated with male breast cancer
215. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer
216. Association between CYP17 polymorphisms and the development of breast cancer
217. CYP17 genotype and breast cancer risk
218. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer
219. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility
220. CYP17 and breast cancer risk: The polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1
221. CYP17 polymorphism in the groups of distinct breast cancer susceptibility: Comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women
222. Association between CYP17 gene polymorphism and risk of breast cancer in young women
223. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer
224. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19)
225. A rare CYP19 (aromatase) variant may increase the risk of breast cancer
226. Aromatase and breast cancer susceptibility
227. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk
228. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk
229. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk
230. Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity
231. Estrogen receptor variants in clinical breast cancer
232. Estrogen receptor mutations in tamoxifen-resistant breast cancer
233. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer
234. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors
235. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors
236. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism
237. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
238. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty
239. Ovarian carcinoma-associated Taql restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion
240. Mendelian inheritance of a Taql restriction fragment length polymorphism due to an insertion in the human progesterone receptor gene and its allelic imbalance in breast cancer
241. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer
242. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer
243. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50
244. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome
245. Male breast cancer and the androgen receptor gene
246. Modification of BRCA1 -associated breast cancer risk by the polymorphic androgen-receptor CAG repeat
247. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer
248. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years
249. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders
250. Catechol-O-methyltransferase and breast cancer risk
251. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk
252. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
253. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans
254. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels
255. Biochemical analysis of HLA class I subunits expression in breast cancer tissues
256. HL-A carcinoma of the breast
257. Lack of association between carcinoma of the breast and HL-A specificities
258. HL-A antigens and breast cancer
259. HLA frequencies in cancer: A third study
260. HL-A antigens in solid tumors
261. Positive correlation between breast cancer incidence and HLA antigens
262. Breast cancer and histocompatibility antigens
263. Human leucocytic antigens (HLA) in breast cancer
264. Genetic linkage analysis in a high-risk cancer family: HLA and 24 other markers
265. The biology of cachectin/TNF - A primary mediator of the host response
266. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles
267. Polymorphism in the tumor necrosis factor-alpha promoter region and in the heat shock protein 70 genes associated with malignant tumors
268. Polymorphism of the human TNF-alpha promoter - Random variation or functional diversity?
269. Tumor necrosis factor (TNF) microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases associated with the major histocompatibility complex and TNF secretion
270. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation
271. Human major histocompatibility complex contains genes for the major heat shock protein HSP70
272. Stress proteins and immunology
273. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides
274. The role of iron in cancer
275. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
276. Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: An analysis of 255 heterozygotes
277. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis
278. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders
279. Association of breast cancer progression with a vitamin D receptor gene polymorphism
280. Association of A vitamin D receptor polymorphism with sporadic breast cancer development
281. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer
282. Vitamin D receptor genotype and breast cancer in Latinas
283. Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no 179. Online
284. Somatic mutations of the APC gene in primary breast cancers
285. The APC11307K allele and breast cancer risk
286. The APC11307K allele and cancer risk in a community-based study of Ashkenazi Jews
287. Association of the 11307K APC mutation with hereditary and sporadic breast/ovarian cancer: More questions than answers
288. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk
289. Human familial and sporadic breast cancer: Analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay
290. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
291. TbetaR-1(6A) is a candidate tumor susceptibility allele
292. Linkage of early-onset familial breast cancer to chromosome 17q21
293. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
294. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
295. Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families
296. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13)
297. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
298. Thymocyte apoptosis induced by p53-dependent and independent pathways
299. A single ataxia telangiectasia gene with a product similar to PI-3 kinase
300. Eighth International Workshop on Ataxia-Telangiectasia (ATW8)
301. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
302. Nineteen of 26 cellular oncogenes precisely localized in the human genome map to one of the 83 bands involved in primary cancer-specific rearrangements
303. Isolation and mapping of a cosmid clone containing the human NAT2 gene
304. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic acid substitutions
305. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis
306. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13
307. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
308. A 3-Mb contig from D11S987 to MLK3, a gene-rich region in 11q13
309. Human dioxin-inducible cytochrome P1-450: Complementary DNA and amino acid sequence
310. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: Role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism
311. Report of the committee on the genetic constitution of chromosome 22
312. Purification and reconstitution properties of human placental aromatase. A cytochrome P-450-type monooxygenase
313. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15
314. Molecular epidemiology of breast cancer: Genetic variation in steroid hormone metabolism
315. Estrogen and oncogene mediated growth regulation of human breast cancer cells
316. Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease
317. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique
318. Localization of the human progesterone receptor gene to chromosome 11q22-q23
319. Catechol-O-methyl transferase: Pharmacological aspects and physiological role
320. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2
321. The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with Bgll
322. Nuclear localization of catechol-O-methyltransferase in neoplastic and nonneoplastic mammary epithelial cells
323. Assignment of the human UDP glucuronosyltransferase gene (UGT1A1) to chromosome region 2q37
324. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
325. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues
326. Heat shock cognate 70 mutations in sporadic breast carcinoma
327. The structural gene for transferrin (TF) maps to 3q21-3qter
328. Effect of 1 alpha, 25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions
329. The human vitamin D receptor gene (VDR) is localized to region 12cen-q12 by fluorescent in situ hybridization and radiation hybrid mapping: Genetic and physical VDR map
330. Induction of differentiation by 1 alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors
331. Reduced expression of APC and DCC gene protein in breast cancer
332. The locus for apolipoprotein E (apoE) is linked to the complement component C3 (C3) locus on chromosome 19 in man
333. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion
334. The gene for 17 beta-hydroxysteroid dehydrogenase maps to human chromosome 17, bands q12-q21, and shows an RFLP with Scal
335. A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro
336. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
337. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
338. Assignment of human transforming growth factor-beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33-q34 and 1p32-p33, respectively